Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas

Area of Science:

• Endocrinology and Metabolism
• Neuroscience
• Cell Biology

Background:

• Glucagon-like peptide-1 (GLP-1) is crucial for managing diabetes by stimulating insulin secretion.
• Exendin-4, a GLP-1 receptor agonist, is investigated for its cellular mechanisms in diabetes.
• Streptozotocin (STZ)-induced diabetes in mice serves as a model to study therapeutic interventions.

Purpose of the Study:

• To elucidate the cellular mechanisms underlying exendin-4's effects in STZ-induced diabetic mice.
• To investigate the role of the nerve growth factor (NGF)/p75 neurotrophin receptor (p75NTR) system in exendin-4's action.
• To assess the impact of exendin-4 on glucose regulation, insulin secretion, and oxidative stress markers.

Main Methods:

• BALB/c male mice were divided into four groups: control, exendin-4 alone, STZ-induced diabetes, and STZ + exendin-4.
• Exendin-4 (3 microg/kg) was administered subcutaneously daily for 30 days post-STZ induction.
• Measurements included plasma glucose, insulin, somatostatin expression, p75NTR, NGF, islet cell proliferation (PCNA), apoptosis, and antioxidant enzyme activities (catalase, GPx, SOD).

Main Results:

• Exendin-4 treatment suppressed STZ-induced plasma glucose increase and somatostatin expression.
• Insulin reduction was inhibited; p75NTR, NGF, and NGF-positive islet cells increased.
• Pancreatic antioxidant enzyme activities (catalase, glutathione peroxidase, superoxide dismutase) were significantly elevated.

Conclusions:

• Exendin-4 exerts therapeutic effects in diabetic mice, potentially via the NGF/p75NTR pathway.
• Exendin-4 treatment mitigates hyperglycemia and oxidative stress in STZ-induced diabetes.
• The study suggests exendin-4's ability to decrease somatostatin expression contributes to its beneficial actions.